Compare Ascendis Pharma A/S (ASND) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Stanley Black & Decker, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Stanley Black & Decker, Inc. trades at $88.22 (market cap $13.71B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays a 3.76% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SWK | |
|---|---|---|
Market Cap | $17.74B | $13.71B |
Sector | Health | — |
52-Week High | $277.18 | $94.12 |
52-Week Low | $163.32 | $62.12 |
Enterprise Value | $18.11B | $19.88B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Stanley Black & Decker (SWK) trades at $88.22, up 1.61% with a bullish technical signal and consistent earnings beats. The stock shows strong valuation metrics with P/S of 0.88 and P/B of 1.53, while profitability remains modest with 2.44% net margin. Recent corporate actions include a $0.83 dividend payment, and cash flow trends indicate operational stability despite slight net outflows.
SWK presents a mixed outlook with positive earnings momentum and aerospace/automotive demand offset by Tools & Outdoor segment weakness and elevated debt. Analyst consensus leans neutral (51% Hold) with $82.75 price target below current levels. Key risks include consumer sentiment pressures and high debt load, though cost-saving initiatives support turnaround potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
